FDA cleared the LTZ Therapeutics’s Investigational New Drug application for LTZ-301, a first-in-class myeloid engager immunotherapy intended to treat relapsed or refractory non-Hodgkin lymphoma.
Tempus AI Inc. and Stemline Therapeutics Inc. announced a new collaboration. The two companies will leverage Next—Tempus’ AI-enabled care pathway intelligence platform—to help clinicians determine when an ESR1 test may be appropriate.
DeepHealth and ConcertAI’s TeraRecon announced a strategic collaboration to integrate certain capabilities to advance imaging tools and the radiology workflow.
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
An estimated 5,200 of HHS employees have been fired during the course of this week. Since the firings are ongoing, no final tally of their extent exists. At this writing, approximately 1,200 of the fired HHS employees were working at NIH, about 700 at FDA, and 750 at CDC.
Cancer data quoted in President Trump’s executive order last week have raised eyebrows among experts in cancer epidemiology.
Today, our world is small. It feels smaller all the time. In a few hours we can get to any point on the globe.
As cancer clinicians, we spend years learning how to think objectively and rationally when supporting patients who have responded to a cancer diagnosis with anger and fear.
Dan Theodorescu was named director of the University of Arizona Cancer Center.
The NRG Oncology Group Chairs created the position of associate group chair and selected Charles E. Geyer to fill the position, effective immediately. He will serve alongside the three NRG Oncology group chairs, Quynh-Thu Le, Robert Mannel, and Norman Wolmark.
